Skip to main content
Erschienen in: Acta Diabetologica 11/2019

29.03.2019 | Case Report

Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment

verfasst von: C. Cosentino, M. Contento, M. Paganini, E. Mannucci, B. Cresci

Erschienen in: Acta Diabetologica | Ausgabe 11/2019

Einloggen, um Zugang zu erhalten

Excerpt

Mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome are a maternally inherited mitochondrial genetic disorder characterized by defective oxidative phosphorylation. The adenine-to-guanine transition at position 3243 in the MT-TL1 gene is the most common mutation of mitochondrial DNA found in patients with MELAS syndrome. As other mitochondrial disorders, MELAS syndrome can develop in the neonatal phase, childhood, or adulthood, and show a broad spectrum of clinical presentations. Neurological and muscular disturbances (i.e., stroke-like episodes, recurrent migrainous headaches, seizures, and muscle weakness with exercise intolerance) are the earliest and most frequent manifestations of the disease. However, mitochondrial diseases, including MELAS syndrome, are multi-organ disorders including cardiomyopathy, nephropathy, hypothyroidism, and diabetes (DM). …
Literatur
1.
Zurück zum Zitat Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624CrossRef Yatsuga S et al (2012) MELAS: a nationwide prospective cohort study of 96 patients in Japan. Biochim Biophys Acta 1820(5):619–624CrossRef
2.
Zurück zum Zitat Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7CrossRef Divakaruni SA et al (2013) Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc Natl Acad Sci USA 110(14):5422–7CrossRef
3.
Zurück zum Zitat El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69CrossRef El-Hattab AW et al (2014) Glucose metabolism derangements in adults with the MELAS m.3243A > G mutation. Mitochondrion 18:63–69CrossRef
4.
Zurück zum Zitat Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506CrossRef Maedler K et al (2005) Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 90:501–506CrossRef
5.
Zurück zum Zitat Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54CrossRef Artuso R et al (2015 Feb) Therapeutic implications of novel mutations of the RFX6 gene associated with early-onset diabetes. Pharmacogenomics J 15(1):49–54CrossRef
Metadaten
Titel
Therapeutic options in a patient with MELAS and diabetes mellitus: follow-up after 6 months of treatment
verfasst von
C. Cosentino
M. Contento
M. Paganini
E. Mannucci
B. Cresci
Publikationsdatum
29.03.2019
Verlag
Springer Milan
Erschienen in
Acta Diabetologica / Ausgabe 11/2019
Print ISSN: 0940-5429
Elektronische ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-019-01302-z

Weitere Artikel der Ausgabe 11/2019

Acta Diabetologica 11/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.